Citations

Mayo Clinic

Showing 10 of 108585 citations.

Disruption of dopamine homeostasis has sexually dimorphic effects on senescence characteristics of Drosophila melanogaster
Bednářová, Andrea , Hanna, Marley E., Rakshit, Kuntol, O’Donnell, Janis M., Krishnan, Natraj , Krishnan, Natraj

European Journal of Neuroscience | January 23, 2017 | Volume: 45 | Issue: 6 | Pages: 816-825

10.1111/ejn.13525 | PMID 28112452 Get It

AbstractThe neurotransmitter dopamine (DA) is known to be involved in a multitude of physiological processes. We investigated sexually dimorphic effects of disruptions in DA homeostasis and its relationship to senescence using three different Drosophila melanogaster mutants namely Catsup (Catsup26) with elevated DA levels, and pale (ple2), Punch (PuZ22) with depleted DA levels. In all genotypes including controls, DA levels were significantly lower in old (45–50‐day‐old) flies compared with young (3–5‐day‐old) in both sexes. Interestingly, females had lower DA content than males at young age whereas this difference was not observed in old age, suggesting that males had a larger decline in DA levels with age. Females, in general, were longer lived compared with males in all genotypes except ple2 mutants with depleted DA levels. This phenotype was abolished in the ple2 rescue flies. Interestingly, females also demonstrated marked age‐related decline in circadian locomotor activity compared with males. Old Catsup26 males with elevated DA levels accumulated significantly lower levels of lipid peroxidation product 4‐hydroxy 2‐nonenal (4‐HNE) compared with age‐matched wild type, ple2 and PuZ22 mutant males. In Catsup26 revertant lines this phenomenon was absent. We also observed a sexually dimorphic response in the expression levels of key stress and aging associated and/or related transcription factor genes across genotypes with elevated or depleted DA levels which was reverted to wild type levels in specific rescue lines. Taken together, our results reveal a novel sexually dimorphic involvement of DA in senescence characteristics of D. melanogaster.
Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential
Kuriya, Bindee , Cohen, Marc D., Keystone, Ed

Therapeutic Advances in Musculoskeletal Disease | January 23, 2017 | Volume: 9 | Issue: 2 | Pages: 37-44

10.1177/1759720x16687481 | PMID 28255337 Get It

Biologics have changed expectation and outcomes for rheumatoid arthritis (RA). However, the optimal duration and sequence of therapy for this disease has yet to be determined. Also, a significant number of patients do not satisfactorily respond to currently available therapies. The Janus kinase (JAK) inhibitors represent a new class of therapies for RA. These drugs work uniquely by inhibiting intracellular pathways thought to be important in the pathogenesis of RA. They are available as oral agents, which is also different from the currently available biologics. Baricitinib has now been evaluated in four phase III clinical trials, and although safety concerns cannot fully be answered until the drug is studied over longer periods of time, the data to date suggest that this drug with its once daily dosing, rapid onset of action and efficacy as monotherapy represents an important addition to the RA therapeutic armamentarium. Further study and experience will better define how baricitinib will be used and by which patients.
Impact of Pancreatic Cyst Fluid CEA Levels on the Classification of Pancreatic Cysts Using the Papanicolaou Society of Cytol
Saieg, Mauro Ajaj, Munson, Valerie, Colletti, Shanna, Nassar, Aziza, Saieg, Mauro Ajaj, Munson, Valerie, Colletti, Shanna, Nassar, Aziza

Diagnostic Cytopathology | January 22, 2017 | Volume: 45 | Issue: 2 | Pages: 101-106

10.1002/dc.23633 | PMID 28110503 Get It

BackgroundThe new proposed classification for pancreaticobiliary cytology has advocated the use of carcinoembryonic antigen (CEA) analysis of cyst fluid as an ancillary diagnostic tool for the determination of mucinous neoplasms in pancreatic cyst aspirates. We aimed to investigate the effect of CEA cyst fluid analysis on cases primarily called negative or nondiagnostic and on the sensitivity and specificity of the method.MethodsWe retrospectively identified and collected all pancreatic cyst aspirates from 2010 to 2014 at Mayo Clinic, Jacksonville, Florida, along with available corresponding surgical diagnoses. Cases primarily classified as nondiagnostic or negative but that had a cyst CEA level of 192 ng mL−1 or higher were reclassified as mucinous neoplasms. Cytohistologic correlation was assessed whenever possible.ResultsWe retrieved pancreatic cyst aspirates from 255 patients who had a corresponding CEA level measurement. Median patient age was 70 years (range, 25–100 years). Among all samples, 129 (50.6%) had been classified as negative and 42 (16.4%) as nondiagnostic. Applying the new criteria, the number of samples previously classified as negative and nondiagnostic decreased considerably, with a statistically significant difference among negative cases. Fifty‐four cases (21.2%) had an available corresponding surgical diagnosis, and complete agreement was achieved in 95.4% of the cases. Use of the new cutoff for CEA levels increased the sensitivity and negative predictive value, compared with the original diagnoses.ConclusionsThe incorporation of the new proposed terminology and CEA fluid analysis has significantly decreased the number of samples primarily classified as negative and nondiagnostic, along with improved test characteristics. Diagn. Cytopathol. 2017;45:101–106. © 2016 Wiley Periodicals, Inc.
Surgical Repair of Moderate Ischemic Mitral Regurgitation—A Systematic Review and Meta-analysis
Reddy, Yogesh N.V. , Alla, Venkata , Baskaran, Janani , Kanmanthareddy, Arun , Suri, Rakesh M. , Narayanan, Mahesh Anantha , Aggarwal, Saurabh , Nishimura, Rick

The Thoracic and Cardiovascular Surgeon | January 21, 2017 | Volume: 65 | Issue: 06 | Pages: 447-456

10.1055/s-0036-1598012 | PMID 28109210 Get It

Introduction Moderate mitral regurgitation (MR) of ischemic etiology has been associated with worse outcomes after coronary artery bypass grafting (CABG). Studies comparing concomitant mitral valve replacement/repair (MVR/Re) with CABG and standalone CABG have reported conflicting results. We performed a systematic review and meta-analysis of the published literature. Patients and Methods We searched using PubMed, Cochrane, EMBASE, CINAHL, and Google scholar databases from January 1960 to June 2016 for clinical trials comparing CABG to CABG + MVR/Re for moderate MR. Pooled risk ratio or mean difference (MD) with 95% confidence intervals (CI) for individual outcomes were calculated using random effects model and heterogeneity was assessed using Cochrane's Q-statistic. Results A total of 11 studies were included. Mean follow-up was 35.3 months. All-cause mortality (Mantel–Haenszel [MH] risk ratio [RR]: 0.96, 95% CI: 0.75–1.24, p = 0.775), early mortality (MH RR: 0.65, 95% CI: 0.39–1.07, p = 0.092), and stroke rates (MH RR 0.65, 95% CI: 0.21–2.03, p = 0.464) were similar between CABG and CABG + MVR/Re groups. Adverse event at follow-up was lower with CABG (MH RR: 0.90, 95% CI: 0.61–1.32, p = 0.584). MD of change from baseline in left ventricular (LV) end-systolic dimension (MD: − 2.50, 95% CI: − 5.21 to − 0.21, p = 0.071) and LV ejection fraction (MD: 0.48, 95% CI: − 2.48 to 3.44, p = 0.750) were not significantly different between the groups. Incidence of moderate MR (MH RR: 3.24, 95% CI: 1.79–5.89, p < 0.001) was higher in the CABG only group. Conclusion Addition of MVR/Re to CABG in patients with moderate ischemic MR did not result in improvement in early or overall mortality, stroke risk, or intermediate markers of LV function when compared with CABG alone.
Early Gains in Renal Function Following Implantation of HeartMate II Left Ventricular Assist Devices May Not Persist to One Year
Hasin, Tal , Grupper, Avishay , Maleszewski, Joseph J. , Li, Zhuo , Topilsky, Yan , Frantz, Robert P. , Edwards, Brooks S., Pereira, Naveen L. , Maltais, Simon, Stulak, John M., Joyce, Lyle D., Daly, Richard C. , Park, Soon J., Kushwaha, Sudhir S. , Dillon, John , Frantz, Robert P , Topilsky, Yan

ASAIO Journal | January 21, 2017 | Volume: 63 | Issue: 4 | Pages: 401-407

10.1097/mat.0000000000000511 | PMID 28114196 Get It

Renal function improves early after left ventricular assist device (LVAD) implantation but later decline has been observed. We sought to determine the occurrence and evaluate possible causes for this decline. In 62 consecutive patients with HeartMateII LVAD with available calculated glomerular filtration rate (GFR, ml/min/1.73 m2) 1 year after implant, GFR was assessed repeatedly and possible predictors for decline from 3 to 12 months were investigated. Post-mortem renal specimens for patients supported with an LVAD were evaluated. GFR 54.5 ± 19.5 at admission increased to 66.4 ± 22.3 preoperatively and to 79.2 ± 30.1 ~1 month after implantation. Subsequently at ~3 months GFR declined to 74.7 ± 25.4, at ~6 months to 68.8 ± 23.1, and ~1 year after implant to 63.9 ± 17.7. Glomerular filtration rate at 1 year was significantly lower (p < 0.0001, p < 0.0001, p = 0.005) than GFR 1, 3, and 6 months after implant. Early rise in GFR after surgery was not associated with late decline. Shorter bypass time (β = −0.09, p = 0.048) and higher albumin 3 months after LVAD (β = 14.4, p = 0.025) were significantly associated with less later decline in GFR. Arteriosclerosis was identified in autopsy renal specimens. In conclusion, early gains in renal function after LVAD implant are not sustained in many patients. Patient, device, and operative factors may influence long-term renal function in these patients.
Detection of ALECT2 amyloidosis by positron emission tomography–computed tomography imaging with florbetapir
Ramı́rez-Alvarado, Marina , Nasr, Samih H. , Kemp, Bradley J. , Johnson, Geoffrey B. , Johnson, Geoffrey B. , Ramirez-Alvarado, Marina, Leung, Nelson , Johnson, Geoffrey B , Ramirez-Alvarado, Marina , Johnson, Geoffrey B

British Journal of Haematology | January 20, 2017 | Volume: 177 | Issue: 1 | Pages: 12-12

10.1111/bjh.14519 | PMID 28107549 Get It

Positron emission tomography/computed tomography imaging of adrenocorticotropic hormone-producing small-cell neuroendocrine carcinoma of the cervix
Nguyen, Vien X., Lam‐Himlin, Dora , Nguyen, Ba D. , Lam-Himlin, Dora M

International Journal of Gynecology & Obstetrics | January 20, 2017 | Volume: 137 | Issue: 2 | Pages: 197-198

10.1002/ijgo.12104 | PMID 28106911 Get It

Implementing Genomic Clinical Decision Support for Drug-Based Precision Medicine
Freimuth, Robert R. , Formea, CM, Jm, Hoffman, Matey, Eric T. , Peterson, JF, Boyce, RD, Peterson, Josh F. , Peterson, JF, Freimuth, Robert R , Peterson, Josh F

CPT: Pharmacometrics & Systems Pharmacology | January 20, 2017 | Volume: 6 | Issue: 3 | Pages: 153-155

10.1002/psp4.12173 | PMID 28109071 Get It

Evaluation of a 24‐gene signature for prognosis of metastatic events and prostate cancer‐specific mortality
Pellegrini, Kathryn L. , Sanda, Martin G. , Patil, Dattatraya , Long, Qi , Santiago‐Jiménez, María , Takhar, Mandeep, Erho, Nicholas , Yousefi, Kasra, Klein, Eric A. , Jenkins, Robert B. , Karnes, R. Jeffrey , Moreno, Carlos S. , Davicioni, Elai , Klein, Eric A , Patil, Dattatraya H , Long, Qi

BJU International | January 20, 2017 | Volume: 119 | Issue: 6 | Pages: 961-967

10.1111/bju.13779 | PMID 28107602 Get It

Objectives To determine the prognostic potential of a 24‐gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer‐specific mortality (PCSM) after radical prostatectomy (RP). Patients and Methods Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time‐dependent c‐index analysis, Cox proportional hazards regression and Kaplan–Meier survival analysis. Results Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time‐to‐event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95% confidence interval [CI]: 1.96–7.29; P < 0.001) or of PCSM (HR 6.54, 95% CI: 2.16–19.83; P < 0.001). Conclusions The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer.
Potential epigenetic biomarkers of obesity-related insulin resistance in human whole-blood
Day, Samantha E. , Coletta, Richard L., Kim, Joon Young , Campbell, Latoya E., Benjamin, Tonya R., Roust, Lori R., Filippis, Elena A. De, Mandarino, Lawrence J. , De Filippis, Elena A, Garcia, Luis Alberto , Coletta, Dawn K.

Epigenetics | January 20, 2017 | Volume: 12 | Issue: 4 | Pages: 254-263

10.1080/15592294.2017.1281501 | PMID 28106509 Get It